Difference between revisions of "Duloxetine-moclobemide"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
| caveat =   
 
| caveat =   
 
{{caveSS}}
 
{{caveSS}}
 +
|info =
 +
{{review}}
 
}}
 
}}

Revision as of 14:49, 2 November 2015

Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from duloxetine to moclobemide.[1] [2]

Nietinrijdenbord.png Stop duloxetine
  • Before day 1: gradually reduce dosage of duloxetine to a maximum of 30 mg/ day. When a dosage of 30 mg/day is reached, stop administration.
Eenrichtingbord.png Start moclobemide

A wash-out period of one week is necessary.

  • Day 1-7: wash-out period
  • Day 8: start administration of moclobemide is a normal dosage of 300 mg/day.
Letopbord.png Cave
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.